💰 The Economic Cost of Obesity: Why Governments Might Subsidize GLP-1s

Alex Bennett

8d • General discussion

💰 The Economic Cost of Obesity: Why Governments Might Subsidize GLP-1s – A Quick Breakdown

The Scale of the Crisis

40%+ US adults live with obesity
$170–260B annual direct medical costs
Broader economic & societal costs far higher

Cost-Effectiveness

ICER: GLP-1s meet cost-effectiveness thresholds
Tirzepatide: ~$53K/QALY
Semaglutide: ~$61K/QALY
However, potential users create $100B+ annual spending

Do They Pay for Themselves?

2026 NBER analysis: No reduction in downstream medical spending. Non-GLP-1 spending increases (outpatient care). Cost savings likely only over longer horizons or through non-medical channels.

Societal Perspective

50% treatment of obesity class II/III:

Reduces obesity prevalence by ~33%
Reduces class II/III expenses by 12.9% (€108.7M)
~40% cost reduction per patient over life cycle

Government Approaches

🇦🇺 Australia: PBS listing for BMI≥35 (or ≥32.5 for certain ethnicities), slow roll-out, price reduction required
🇬🇧 UK: Funded for BMI≥30 (1 comorbidity) since 2023; Mounjaro for BMI≥35 (limited to 220K patients)
🇺🇸 US: MFN policy at $245/month → $73.9B Medicare spend over 10 years. Cost neutrality at ~$150/month

Global Equity

WHO updated essential medicines list to include GLP-1RAs
Annual cost >$8K puts them out of reach for most LMICs

Challenges

Long-term benefit tracking (up to 10 years)
Risk of malnutrition & muscle loss
Could worsen diet culture & fat phobia

Takeaway:

GLP-1s are clinically & societally beneficial but don't yet pay for themselves. Governments likely to pursue selective subsidization: targeting highest-risk patients, negotiating lower prices, and implementing managed access.

🔬 For research-grade peptides, check OrionPeptide.com.

🎉 20% OFF Sitewide—Discount Automatically Applied at Checkout

⚠️ Research only. Not for human consumption.

0 comments

💰 The Economic Cost of Obesity: Why Governments Might Subsidize GLP-1s – A Quick Breakdown